AIM Breakfasts

AIM BREAKFAST – 17th August 2016

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 1,006

Total number of AIM Companies trading: 990*
* As at 16 August 2016

Dish of the Day:

No Primary today

Off the Menu:

Darty (DRTY) delisted from Main Market following completion of acquisition by Fnac

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): *

Total number of ISDX Growth Market Companies trading: *
* As at 16 August 2016

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

LoopUp—The provider of conference calls and online meetings is seeking to join AIM. 2015 revs of £9.2m and EBITDA of £1.02m

Bacanora Lithium— To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap

Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 6 September

Autins Group plc – The acoustic and thermal insulation specialist now looks to join AIM late August

 

Breakfast Buffet

Newmark Security (NWT.L) 1.725p £8.1m

The provider of electronic & physical security systems, announced prelims for FYApr16. Revenue from  Asset Protection Division lower due to lower volumes of some major customer programmes. Operating profit affected by new market/product developments. Turnover -4.5% to £21.8m. EPS of 0.26p vs 0.48p. Divi of 0.1p maintained. Cash of £4.3m. Current year profits to be significantly lower. New product launches and cash  building for  future. <0.5x sales. 6.6x PE.

 

AEC Education (AEC.L) 2.25p £1.8m

The provider of educational services in Europe and the Far East  has reported FYDec2015 results. Revenues down to £7.7m from £8.1m. Pre-tax loss of £1.4m vs £1.5m. “The restructuring of the operations in Singapore and London is now complete and this combined with the return to profit in Malaysia and the continuing investment enabled by the sale of our operations in Ireland creates a platform from which AEC can continue to rebuild group profitability.”

 

Imaginatik (IMTK.L) 1.88p £2.85m

The innovation company announced FYMar16 Finals.  Revenue increased by 16% £3.89m. Completion post year end of £1.67m (gross) equity placing and Open Offer. Net loss of £0.95m vs £1.47m.    3 new customers secured in the first quarter of the year, all for operational consulting engagements. Full service innovation offering has greatly improved customer retention since 2012.

 

Tracsis (TRCS.L) 430p £118.45m

The provider of software and services for the traffic data and transportation industry, has  announced that it has signed a significant order with a North American Class 1 railroad operator for its Remote Condition Monitoring (RCM) technology, which marks the Group’s first major contract in North America.  The total order value is in excess of $0.4m and is expected to be fulfilled before the end of 2016.  FYJul2016E forecasts looking for £29.7m revs and EPS of 20.57p. 20.8x PE

 

One Media iP Group (OMIP.L) 3.5p £2.49m

The digital media content provider, which consolidates, exploits and monetises intellectual property rights around music and video, announced it has completed the filming of a video pilot for a new Men & Motors series to be pitched to all major broadcasters both in the UK and on the international broadcast market.  The show is hosted by Boyzone’s Shane Lynch and Mercedes’s corporate and CNBS’s FI presenter Torie Campbell. The format of the new show is targeted at ‘late teens to thirty cools’.

 

Public Service Properties Investments (PSPI.L) 477.5p £181.12m

H1Jun16 numbers from the former specialist real estate investment and financing company. NAV/Share 55.8p. The company has sold all of its investment properties and expects a final return of capital before Q12017.

 

Oncimmune Holdings (ONC.L) 116p £59.2m

The early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announced that it has appointed Andrew Millet as Chief Financial Officer.  He has been interim CFO since June and has over 20 years of relevant experience. He commented “I have great belief in the autoantibody tests that can detect cancer up to four years earlier than other methods and look forward to playing a part in their continued success.”

 

Shanta Gold (SHG.L) 9.13p £53.2m

HY Jun 16 results from the East Africa-focused gold producer.  Gold production of 48,237 oz) (H1 2015: 28,180 oz); H1 gold sales of 47,621 oz at an average price of US$1,193 per oz  compared to average spot price of US$1,222 /oz (H1 2015: 25,142 oz at an average price of US$1,238 /oz). Revs of $55.7m vs $31.9m. EBITDA marginally up at $33.3m. Annual production guidance maintained for 2016 of 82,000 – 87,000 oz and expected to be towards the upper end of guidance. 4.5x PE.

 

Evgen Pharma  (EVG.L) 24.75p £18.1m

The clinical stage drug development company focused on the treatment of cancer and neurological conditions, announced that it has received a Clinical Trial Approval from the UK’s regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer.  The primary objectives of the STEM trial are to evaluate safety and efficacy (via tumour imaging) in patients starting to become resistant to mainstream hormone therapy.

 

Access Intelligence (ACC.L) 5.5p £14.7m

The supplier of SaaS solutions for reputation & operational risk management, announced H1May16 results. Revenue from continuing operations up to £5.5m (H1 2015 restated: £2.0m), reflecting acquisition activity. Revenue from existing continuing operations increased to £2.1 million (H1 2015 restated: £2.0 million).  Total loss from continuing operations of £1.2 million. Undertaken ‘significant restructuring’ to reduce costs/allow focus on its core business with a view to improving performance in 2017.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.